A breakthrough Chinese gene‑editing therapy, CS‑101 injection, has been featured in the prestigious journal *Nature*, marking the first time a Chinese‑developed gene‑editing drug for thalassemia appears in a top‑tier scientific publication. The study, a collaboration between Correct Sequence Biotechnology, ShanghaiTech University and the Shanghai Clinical Research Center, shows that CS‑101 can permanently correct the genetic defect that causes β‑thalassemia. In five patients, the treatment rapidly rebuilt healthy blood‑forming cells, lifted hemoglobin levels and eliminated the need for transfusions. To date, nearly 20 patients with β‑thalassemia or sickle‑cell disease have been cured, staying transfusion‑free for up to 28 months. CEO Mou Xiaodun says the company will now push into other chronic diseases such as cardiovascular and metabolic disorders, leveraging its base‑editing platform to bring durable, affordable cures worldwide. At the same time, GSK announced that China’s regulator has approved Eucrizza (benralizumab) combined with nasal steroids for adults suffering from chronic rhinosinusitis with nasal polyps—a condition often resistant to steroids or surgery. The drug, already cleared for severe eosinophilic asthma, requires only two injections a year, offering a convenient, long‑acting option for patients. Both developments underscore Pudong’s rapid rise as a hub for innovative, patient‑focused medicines.
Read more